Report: More than half of the world's population will be overweight/obese by 2035

Published Date: 08 Mar 2023

The World Health Organization's 2023 Atlas predicts that 51% of the world's population, or more than 4 billion people, will be overweight or obese within the next 12 years.

Read Full News

Latest News

Weight-loss Drugs Fuel Protein-rich Whey Craving

(Corrects description of DFA to cooperative, not collective, in paragraph 8)

Tirzepatide Tied to Less Mortality and AEs Than Semaglutide

Tirzepatide is associated with lower all-cause mortality and reduced adverse gastrointestinal events compared with semaglutide.

Viridian Eye Disease Drug Surpasses Expectations in Late-stage Trial; Shares Soar

Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage ⁠trial in chronic patients, sending its shares up nearly...

Vitamin D Genotyping May Prevent T2D Progression Risk

Vitamin D supplementation has shown some promise in reducing risk for progression from prediabetes to T2D. This study suggests that only people with certain genetic variants may benefit.

Encouraging Short-Term Goals for Older Adults With Diabetes

Small steps can build to long-term gains.

Canada Approves Second Generic Version Of Ozempic

The ⁠Canadian health regulator ⁠said on ⁠Friday that ‌it had approved Canada-based Apotex's generic ‌version of semaglutide, making ‌it ‌the second copycat ⁠version of...

Todays Updates

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Todays Updates

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Latest News

(Corrects description of DFA to cooperative, not collective, in paragraph 8)

Tirzepatide is associated with lower all-cause mortality and reduced adverse gastrointestinal events compared with semaglutide.

Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage ⁠trial in chronic patients, sending its shares up nearly...

Vitamin D supplementation has shown some promise in reducing risk for progression from prediabetes to T2D. This study suggests that only people with certain genetic variants may benefit.

Small steps can build to long-term gains.

The ⁠Canadian health regulator ⁠said on ⁠Friday that ‌it had approved Canada-based Apotex's generic ‌version of semaglutide, making ‌it ‌the second copycat ⁠version of...

News All Time

Gastric Bypass Leads to Diabetes Remission

Laparoscopic one anastomosis gastric bypass achieves sustained diabetes remission in most patients with type 2 diabetes and obesity over 10 years of follow-up.

Oral Acromegaly Drug Performing Well in First Few Patients

Initial real-world results of patients receiving paltusotine suggest reduced symptoms and good tolerability, while a phase 3 trial finds no interaction with levothyroxine.

Gastric Ring Add-On May Aid Weight Loss After Surgery

A ring-augmented one anastomosis gastric bypass achieves greater weight loss than standard surgery in patients with recurrent weight gain or suboptimal outcomes after sleeve gastrectomy.

MASLD Risk May Be Higher in Men Who Eat More Red Meat

Red meat intake showed no overall association with MASLD risk, but higher daily consumption (75-90 g) was linked to increased risk in men.

Childhood Trauma Tied to Gestational Diabetes Risk

Women with prior adverse childhood experiences may face a higher risk for gestational diabetes, with the risk rising with each additional adverse experience, a meta-analysis of 11 studies shows.

FDA Proposes End to Mass GLP-1 Compounding

The agency appears to leave a loophole for patient-specific formulations.

Food Insecurity and Poverty May Raise MASLD Risk in US

People who do not have enough food to eat or who live below the poverty level are more likely to develop MASLD, and this risk is higher in non-Hispanic White individuals.

‘Cyborg’ Islet Cells and Potential New Diabetes Therapies

Researchers combined electronic sensors with human islet cells to create living ‘cyborg’ organoids transmitting troves of previously unseen data on islet cell function.

Canada Approves First Generic Version Of Ozempic Amid Rising GLP-1 Competition

Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's blockbuster diabetes drug Ozempic made ⁠by Indian drugmaker Dr Reddy's Laboratories,...

Autusm Advisory Board Focuses on 'profound Autism,' Improved Medical Care

A U.S. advisory committee appointed by Health Secretary Robert F. Kennedy Jr. recommended on Tuesday that the government adopt the term "profound autism” for those with the...

Migraine Med Shows Weight-Loss Benefit

New data show early and sustained weight loss with atogepant, raising the possibility of metabolic benefits beyond migraine prevention.

HIV Patients in Senegal Skip Treatment Amid LGBTQ Arrests

Fewer patients are visiting some HIV treatment centres in Senegal amid a wave of arrests targeting LGBTQ people, threatening the country's fight against the virus.

Germany to Impose Levy on Sugary Drinks From 2028

Germany plans to impose a levy on sugary drinks under a healthcare reform package that aims to rein in rising rates of ⁠obesity and ease pressure on the health system.

Sleep Disorders Very Common in Patients With Osteoarthritis

While pain is recognized as a likely contributor to poor sleep, the relationship may be bidirectional, with sleep problems also contributing to osteoarthritis symptoms.

Bariatric Surgery Adapts to the GLP-1 Era

As GLP-1 use increases and bariatric surgery rates decline, practices are pivoting to comprehensive obesity care that integrates medical and surgical approaches.

Brolucizumab Beats Laser Treatment in Diabetic Retinopathy

Intravitreal brolucizumab is superior to panretinal laser photocoagulation in preserving visual acuity for patients with proliferative diabetic retinopathy, clinical trial data show.